Fulcrum Therapeutics Inc (NASDAQ:FULC) traded at $3.53 at last check on current trade day and made a downward move of -3.29% on its previous day’s price.
Looking at the stock we see that its previous close was $3.65 and the beta (5Y monthly) reads 2.125 with the day’s price range being $3.5 – $3.87. In terms of its 52-week price range, FULC has a high of $10.13 and a low of $2.32. The company’s stock has gained about 9.97% over that past 30 days.
Fulcrum Therapeutics Inc has a market cap of $190.54 million and is expected to release its quarterly earnings report on 2025-Feb-24.
On the other hand, looking at the outlook for the FULC stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 50% Sell.
Based on estimates by 13 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 4 have rated the Fulcrum Therapeutics Inc (FULC) stock as a Hold, while 9 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is 19.35% off its SMA20 and 10.84% from its 50-day simple moving average. The RSI (14) is pointing at 62.10 while the volatility over the past week is 8.84% and jumps to 8.81% over the past one month. The beta value is 2.15, while the average true range (ATR) is currently pointing at 0.27. The average price target for the stock over the next 12 months is $4, with the estimates having a low of $2 and a high of $23. These price ends are 43.34% and -551.56% off the today’s price level respectively, although investors could be excited at the prospect of a -13.31% if the FULC share price touches on the median price of $4.
Coming back to Fulcrum Therapeutics Inc (NASDAQ:FULC), we note that the average 3-month trading volume was 398.68K, while that of the preceding 10-day period stands at 0.32 million. Current shares outstanding are 53.97 million.
The insiders hold 11.36% of the company’s shares while institutions hold 86.67%. The data shows that short shares as of 2025-03-31, stood at 3.73 million at a short ratio of 8.45. This represents a 896.00 short interest in shares outstanding on 2025-03-31. Shares short fall in March from the previous month at 4.92 million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -24.89% down in year-to-date price movement.
